The Social Community forBiohackers Connect

I do think the having too much data take is interesting. Hypochondriacs are right some of the time, but the rest of the time they could be doing themselves a real disservice.

This has been really helpful. Thanks for sharing.⁠Looking for thoughts from people who’ve researched this. •⁠ ⁠I have a CAC score of 21 despite consistently good cholesterol and metabolic markers. •⁠ ⁠My doctors recommend a statin, but I’m not convinced my numbers suggest an ongoing cholesterol problem. •⁠ ⁠Could this represent an older plaque event rather than current metabolic dysfunction? •⁠ ⁠These labs are representative of my results over the years: Total Chol. 151 <200 ApoB 71 <70–80 LDL-C 89 <70 Lp(a) 14 <30 TG 59 <100 HDL 48 >50 Insulin 6.4 <8 HOMA-IR 1.6 <2.0 hs-CRP 0.63 <1.0 CAC 21 0 I’ll def look into the peptides and supplements mentioned. That seems like a lower overall impact place to start. I’m also looking at doing cleerly to see if there is a bunch of soft plaque?

Demand for knockoff versions of retatrutide, a peptide-based drug being developed by Eli Lilly, has skyrocketed lately, propelling a gray market that likely exceeds $100 million in annual sales, according to an estimate prepared by The Information that examined many of the market’s biggest suppliers. Retatrutide, or reta as it is commonly called, has become popular among the tech elite, who had already shown great interest in other peptide-based drugs. Reta is potentially far more potent, producing greater weight loss and possibly less muscle loss, but it hasn’t yet won approval from the FDA.

Full Circle

The timing for an IPO seems right—health-based wearables are a thing nowadays. Shares of its closest public competitor, Garmin, are up 18.6% so far this year.